• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Brad Perriello

Feds arrest PixarBio CEO Reynolds on securities fraud charges

April 24, 2018 By Brad Perriello

PixarBio CEO Frank Reynolds

The bizarre saga of biotech executive Frank Reynolds took another turn today when federal authorities arrested the PixarBio (OTC:PXRB) CEO and two associates on securities fraud charges, claiming they misled investors about its opioid substitute and falsely claimed a $1 billion valuation. PixarBio is purportedly developing a drug to replace morphine and other opiates, but prosecutors alleged […]

Filed Under: Featured, Legal News, Wall Street Beat Tagged With: PixarBio

Update: Allergan, Takeda spar for Shire

April 19, 2018 By Brad Perriello

Allergan, Takeda spar for Spire

Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer. Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502). Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, […]

Filed Under: Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Allergan, Shire, Takeda Pharmaceutical Co

Johnson & Johnson moves closer to exiting the diabetes business with $2.1B LifeScan sale

March 16, 2018 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) took another step toward the exit door for the diabetes business, agreeing to a $2,1 billion offer from private equity shop Platinum Equity for its LifeScan blood glucose monitoring unit. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: johnsonandjohnson, lifescan

Reva Medical swings to black on first sales

March 9, 2018 By Brad Perriello

Reva Medical

Reva Medical (ASX:RVA) this week reported its first quarterly and annual revenues since winning CE Mark approval for its bioresorbable coronary scaffolds, swinging from red to black for the full year. San Diego-based Reva posted fourth-quarter profits of $160,000, or -10¢ per share, on sales of $28,000 for the three months ended Dec. 31, 2017. That […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Reva Medical

Ex-Advanced BioHealing exec draws probation in VA fraud case

February 12, 2018 By Brad Perriello

Advanced BioHealing

A former Advanced BioHealing executive who admitted to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing last week drew probation in the case. Federal had prosecutors accused Todd Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic […]

Filed Under: Featured, Legal News, Regenerative Medicine, Wound Care Tagged With: Advanced BioHealing, Shire

Varian Medical to pay $1.3B for Sirtex

January 30, 2018 By Brad Perriello

Varian to acquire Sirtex

Varian Medical (NYSE:VAR) yesterday said it agreed to pay nearly $1.3 billion for Australia’s Sirtex Medical (ASX:SRX) and its anti-cancer microspheres. The A$28-per-share offer, which values Sirtex at A$1.59 billion (about $1.28 billion), is slated to close in late May, Palo Alto, Calif.-based Varian said. It’s part of a bid to broaden that company’s oncology portfolio. Sirtex makes […]

Filed Under: Featured, Mergers & Acquisitions, Oncology, Radiosurgery, Wall Street Beat Tagged With: Sirtex Medical, Varian Medical Systems

Report: Chinese bidders eye Johnson & Johnson’s diabetes biz

January 17, 2018 By Brad Perriello

Johnson & Johnson

Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: chinainvestmentcorp, johnsonandjohnson, sinocare

Anika Therapeutics wins FDA nod for bone void filler

December 27, 2017 By Brad Perriello

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) said today that it won 510(k) clearance from the FDA for its hyaluronic acid-based bone void filler The indication covers filling bone voids or defects that aren’t intrinsic to the stability of the bone, created during surgery or the result of traumatic injury. Made of a synthetic, biocompatible bone graft substitute material, […]

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Regulatory/Compliance Tagged With: Anika Therapeutics Inc.

Aerogen, Lyomark ink inhaled surfactant deal

December 7, 2017 By Brad Perriello

Aerogen and Lyomark Pharma said today that they inked a deal to develop an inhaled surfactant treatment for respiratory distress syndrome in pre-term infants. The pact calls for the duo to combine a compound called AP-002, a nasally inhaled surfactant based on a combination of Lyomark’s Alveofact bovine lung surfactant and Aerogen’s PDAP nasal delivery technology. Aerogen […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory Tagged With: Aerogen, Lyomark Pharma

Biocorp inks safety syringe deal with pharma player

November 29, 2017 By Brad Perriello

Biocorp

Biocorp (PAR:ALCOR) said today that it inked a deal for its NewGuard safety syringe technology with “a leading global player specializing in pharmaceutical products” that it’s not allowed to name. The Issoire, France-based company said the deal call for it to integrate and commercialize the NewGuard technology into the pharma partner’s pre-filled heparin syringes, saying […]

Filed Under: Drug-Device Combinations, Featured Tagged With: biocorp

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 14
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS